Affordable Access

deepdyve-link
Publisher Website

Dihydroorotate Dehydrogenase as a Target for the Development of Novel Helicobacter pylori-Specific Antimicrobials.

Authors
  • Ohishi, Tomokazu1
  • Inaoka, Daniel Ken2
  • Kita, Kiyoshi2
  • Kawada, Manabu1, 3
  • 1 Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation.
  • 2 School of Tropical Medicine and Global Health, Nagasaki University.
  • 3 Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation.
Type
Published Article
Journal
Chemical and Pharmaceutical Bulletin
Publisher
Pharmaceutical Society of Japan
Publication Date
Jan 01, 2018
Volume
66
Issue
3
Pages
239–242
Identifiers
DOI: 10.1248/cpb.c17-00796
PMID: 29491257
Source
Medline
Keywords
License
Unknown

Abstract

Helicobacter pylori (H. pylori) infection is the world's most common bacterial infection, affecting approximately 50% of the global population. H. pylori is the strongest known risk factor for stomach diseases, including cancer. Hence, treatment for H. pylori infection can help reduce the risk of these diseases. However, the emergence of drug-resistant strains of H. pylori and the occurrence of adverse effects resulting from current therapies have complicated the successful eradication of H. pylori infection. Although various antibiotics that target several bacterial enzymes have been discovered, dihydroorotate dehydrogenase (DHODH) may hold potential for the development of novel anti-H. pylori agents with reduced toxicity and side effects. Here we review the existing literature that has focused on strategies for developing novel therapeutic agents that target the DHODH of H. pylori.

Report this publication

Statistics

Seen <100 times